Biobot Surgical has entered into a memorandum of understanding (MOU) with BEBIG Medical to offer a robotic-guided high dose rate (HDR) brachytherapy solution to treat prostate cancer.

The iSR’obot Mona Lisa 2.0, developed by Biobot Surgical, is a robotic-assisted percutaneous surgical system that helps doctors in the positioning of needles during image-guided diagnostic and interventional prostate procedures.

The firm claims that using the system for HDR brachytherapy automatically guides the needle insertion by a clinician to within 1.0mm of accuracy of the targeted needle position for treatment.

The robotic arm is designed for a optimal treatment plan with its flexibility for angulated needle trajectory and prevents critical anatomical structures.

BEBIG Medical Chairman and chief executive officer George Chan said: “The future trend of medical device technology was moving toward digitalization, automation and artificial intelligence.

“The joint partnership is a vivid display of these orientations to achieve clinical excellence.”

The iSR’obot Mona Lisa 2.0 has already secured the US Food and Drug Administration (FDA) 510(k) clearance. The system is anticipated to receive EU MDR approval in 2023.

Biobot Surgical’s first-generation iSR’obot Mona Lisa is marketed in EuropeAustralia, and Asia.

iSR’obot Mona Lisa has shown a clinically significant prostate cancer detection rate of 81% higher than cognitive fusion biopsy in clinical studies.

Biobot Surgical chief executive officer Sim Kok Hwee said: “BEBIG Medical is a well-established brand in brachytherapy, while Biobot Surgical is known for its accurate placement of needles.

“The partnership enables our companies to bring robotic-assisted brachytherapy solutions to patients.”